[1] Meyers R.Surgical experiments in the therapy of certain ’extrapyramidal’ diseases:a current evaluation[J].Acta Psychiatr Neurol Suppl,1951,67(1):1-42.
[2] Spiegel EA,Wycis HT,Marks M,et al.Stereotaxic Apparatus for Operations on the Human Brain[J].Science,1947,106(2754):349-350.
[3] Benabid AL,Pollak P,Gervason C,et al.Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus[J].Lancet,1991,337(8738):403-406.
[4] Rehncrona S,Johnels B,Widner H,et al.Long-term efficacy of thalamic deep brain stimulation for tremor:double-blind assessments[J].Mov Disord,2003,18(2):163-170.
[5] Limousin P,Pollak P,Benazzouz A,et al.Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation[J].Lancet,1995,345(8942):91-95.
[6] Siegfried J,Lippitz B.Bilateral chronic electrostimulation of ventroposterolateral pallidum:a new therapeutic approach for alleviating all parkinsonian symptoms[J].Neurosurgery,1994,35(6):1126-1130.
[7] Spiegel J,Fuss G,Backens M,et al.Transient dystonia following magnetic resonance imaging in a patient with deep brain stimulation electrodes for the treatment of Parkinson disease.Case report[J].J Neurosurg,2003,99(4):772-774.
[8] Evidente VG,Premkumar AP,Adler CH,et al.Medication dose reductions after pallidal versus subthalamic stimulation in patients with Parkinson’s disease[J].Acta Neurol Scand,2011,124(3):211-214.
[9] Kleiner-Fisman G,Herzog J,Fisman DN,et al.Subthalamic nucleus deep brain stimulation:summary and meta-analysis of outcomes[J].Mov Disord,2006,21(Suppl) 14:290-304.
[10] Odekerken VJ,van Laar T,Staal MJ,et al.Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson’s disease (NSTAPS study):a randomised controlled trial[J].Lancet Neurol,2013,12(1):37-44.
[11] Sako W,Miyazaki Y,Izumi Y,et al.Which target is best for patients with Parkinson’s disease? A meta-analysis of pallidal and subthalamic stimulation[J].J Neurol Neurosurg Psychiatry,2014,Jan 20.doi:10.1136/jnnp-2013-306090.(Epub ahead of print).
[12] Eusebio A,Chen CC,Lu CS,et al.Effects of low-frequency stimulation of the subthalamic nucleus on movement in Parkinson’s disease[J].Exp Neurol,2008,209(1):125-130.
[13] Tan H,Pogosyan A,Anzak A,et al.Frequency specific activity in subthalamic nucleus correlates with hand bradykinesia in Parkinson’s disease[J].Exp Neurol,2013,240(1):122-129.
[14] Khoo HM,Kishima H,Hosomi K,et al.Low-frequency subthalamic nucleus stimulation in Parkinson’s disease:A randomized clinical trial[J].Mov Disord,2014,29(2):270-274.
[15] Ricchi V,Zibetti M,Angrisano S,et al.Transient effects of 80 Hz stimulation on gait in STN DBS treated PD patients:a 15 months follow-up study[J].Brain Stimul,2012,5(3):388-392.
[16] Schuepbach WM,Rau J,Knudsen K,et al.Neurostimulation for Parkinson’s disease with early motor complications[J].N Engl J Med,2013,368(7):610-622.
[17] Kahn E,D’Haese PF,Dawant B,et al.Deep brain stimulation in early stage Parkinson’s disease:operative experience from a prospective randomised clinical trial[J].J Neurol Neurosurg Psychiatry,2012,83(2):164-170.
[18] Benabid AL,Chabardes S,Mitrofanis J,et al.Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson’s disease[J].Lancet Neurol,2009,8(1):67-81.
[19] Rizzone MG,Fasano A,Daniele A,et al.Long-term outcome of subthalamic nucleus DBS in Parkinson’s disease:From the advanced phase towards the late stage of the disease? [J] Parkinsonism Relat Disord,2014,20(4):376-381.
[20] Lilleeng B,Bronnick K,Toft M,et al.Progression and survival in Parkinson’s disease with subthalamic nucleus stimulation[J].Acta Neurol Scand,2014,Feb 4.doi:10:1111/ane.12224.(Epub ahead of print).
[21] Vedam-Mai V,Gardner B,Okun MS,et al.Increased precursor cell proliferation after deep brain stimulation for Parkinson’s disease:a human study[J].PLoS One,2014,9(3):e88770.
[22] He Z,Jiang Y,Xu H,et al.High frequency stimulation of subthalamic nucleus results in behavioral recovery by increasing striatal dopamine release in 6-hydroxydopamine lesioned rat[J].Behav Brain Res,2014,263(1):108-114.
[23] Emborg ME,Carbon M,Holden JE,et al.Subthalamic glutamic acid decarboxylase gene therapy:changes in motor function and cortical metabolism[J].J Cereb Blood Flow Metab,2007,27(3):501-509.
[24] LeWitt PA,Rezai AR,Leehey MA,et al.AAV2-GAD gene therapy for advanced Parkinson’s disease:a double-blind,sham-surgery controlled,randomised trial[J].Lancet Neurol,2011,10(4):309-319.
[25] Christine CW,Starr PA,Larson PS,et al.Safety and tolerability of putaminal AADC gene therapy for Parkinson disease[J].Neurology,2009,73(20):1662-1669.
[26] Muramatsu S,Fujimoto K,Kato S,et al.A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson’s disease[J].Mol Ther,2010,18(9):1731-1735.
[27] Horger BA,Nishimura MC,Armanini MP,et al.Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons[J].J Neurosci,1998,18(13):4929-4937.
[28] Kordower JH,Herzog CD,Dass B,et al.Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys[J].Ann Neurol,2006,60(6):706-715.
[29] Marks WJ,Jr.,Bartus RT,Siffert J,et al.Gene delivery of AAV2-neurturin for Parkinson’s disease:a double-blind,randomised,controlled trial[J].Lancet Neurol,2010,9(12):1164-1172.
[30] Kordower JH,Emborg ME,Bloch J,et al.Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson’s disease[J].Science,2000,290(5492):767-773.
[31] Jarraya B,Boulet S,Ralph GS,et al.Dopamine gene therapy for Parkinson’s disease in a nonhuman primate without associated dyskinesia[J].Sci Transl Med,2009,1(2):2-4.
